



You are entering a medical section of the Pfizer Landing Page. All materials presented here are for purposes of scientific exchange. They are NOT presented for any promotional purpose

Pfizer Oral Presentations

Oral presentations will be presented in Eastern Standard Time (EST).

Myeloma and Plasma Cell Dyscrasias: Clinical-Pro prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma

Monday, December 13

6:15 PM – 7:45 PM

Room A411-A412

Elranatamab

895

Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-1

Sebag M

[View Presentation](#)

Pfizer Poster Presentations

ASH Poster Presentations will be available for viewing in Hall B5 of the Georgia World Congress Center (Atlanta, GA) and virtually.

Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I

Saturday, December 11

5:30 PM – 7:30 PM

Inotuzumab

1208

The efficacy and safety of low-dose inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia: interim results of a phase 4 study

Ozcan M

[View Presentation](#)

Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

Saturday, December 11

5:30 PM – 7:30 PM

Bosutinib

1475

Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial

Gambacorti-Passerini C

[View Presentation](#)

Myeloma and Plasma Cell Dyscrasias: Clinical-Pro prospective Therapeutic Trials: Poster I

Saturday, December 11

5:30 PM – 7:30 PM

Elranatamab

1674

MagnetisMM-3: an open-label, multicenter, nonrandomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma

Lesokhin A

[View Presentation](#)

Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

Sunday, December 12

6:00 PM – 8:00 PM

Hall B5

Bosutinib

2557

Efficacy and safety of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: final 3-year results of a phase 2 study

Ono T

[View Presentation](#)

Health Services Research—Lymphoid Malignancies: Poster II

Sunday, December 12

6:00 PM – 8:00 PM

Inotuzumab

3012

A pilot study of the application of natural language understanding to identify insights on acute lymphocytic leukemia and its treatment from social media data

Crawford R

[View Presentation](#)

View additional Pfizer congress materials:

[PMI Congress Portal](#)